The focus is currently on K-ras4B (herafter K-ras) specific inhibitors, as K-ras is the most frequently mutated Ras isoform and was recently established as a specific driver of stemness in cancer cells and target of cancer stem cell drugs [12, 13]. This evidence concerns the gene KRAS and cancer.